Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
An announcement from Medmira ( (TSE:MIR) ) is now available.
MedMira Inc. has received Investigational Testing Authorizations from Health Canada to begin clinical trials for self-testing and non-professional use of its Multiplo® TP/HIV rapid test. This move is significant amid rising syphilis and HIV cases in Canada, especially in the Prairie regions, as it aims to provide accessible testing options for individuals who face barriers to healthcare. The trials, supported by the Canadian Institutes of Health Research, will be conducted by REACH Nexus at the MAP Centre for Urban Health Solutions. The tests are designed to offer quick, reliable results from a single finger-prick blood sample, potentially allowing users to confirm positive results through lab tests and access treatment promptly.
More about Medmira
MedMira Inc. is a healthcare company that specializes in the development and commercialization of rapid diagnostic tests. Its primary products include the Multiplo® TP/HIV rapid test, which focuses on providing solutions for detecting syphilis and HIV. The company aims to expand access to testing, particularly in underserved markets affected by rising infection rates.
YTD Price Performance: 13.64%
Average Trading Volume: 94,595
Technical Sentiment Consensus Rating: Sell
Current Market Cap: C$94.79M
For a thorough assessment of MIR stock, go to TipRanks’ Stock Analysis page.
